Gout is a condition that resulted from deposition of monosodium urate crystals in various tissues (eg joints, connective tissue, kidney).
The patient experiences acute and chronic arthritis, soft tissue inflammation, tophus formation, gouty nephropathy and nephrolithiasis.
Primary hyperuricemia is called when uric acid saturation arises without coexisting diseases or drugs that alter uric acid production and excretion.
While in secondary hyperuricemia there is an excessive uric acid production or diminished renal clearance that occurs as a result of a disease, drug, dietary product or toxin.
Febuxostat does not appear to be more cardiotoxic than allopurinol in the treatment of elderly gout patients with or without cardiovascular comorbidities, according to a recent study. Neither drug is associated with elevated risks of cardiovascular events and all-cause mortality.
Both the extended- and immediate-release formulations of febuxostat are effective and well tolerated in the treatment of gout patients with normal or impaired renal function, according to the results of a phase III trial.
A robust association exists between crystal-proven gout and increased prevalence of cardiovascular disease (CVD), a recent study has found. Additionally, characteristic gout severity factors correlate with CVD in patients with gout.
Patients with type 2 diabetes (T2D) experienced reductions in plasma uric acid concentrations and subsequently, fewer gout events following treatment with fenofibrate, according to a post hoc analysis of the FIELD* trial.
New drug applications approved by US FDA as of 16 - 31 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The addition of lesinurad to febuxostat appears to provide superior serum urate-lowering benefit compared with febuxostat alone, with acceptable safety profile and clinically significant effect on tophi, in patients with tophaceous gout requiring additional therapy, according to the results of a 12-month, phase III trial.
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.